Product Datasheet

eIF-2a(Phospho-S51) Conjugated Antibody

Catalog No: #C13338

Package Size: #C13338-AF350 100ul #C13338-AF405 100ul #C13338-AF488 100ul

#C13338-AF555 100ul #C13338-AF594 100ul #C13338-AF647 100ul

#C13338-AF680 100ul #C13338-AF750 100ul #C13338-Biotin 100ul

Orders: order@signalwayantibody.com

Support: tech@signalwayantibody.com

Description

Product Name	eIF-2a(Phospho-S51) Conjugated Antibody
Host Species	Rabbit
Clonality	Monoclonal
Species Reactivity	Hu
Immunogen Description	recombinant protein
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Other Names	Antigen LB39 AA antibody Antigen LB39-AA antibody Antigen SK29 AA antibody Antigen SK29-AA antibody MAR1_HUMAN antibody MART 1 antibody MART-1 antibody MART1 antibody Melan A antibody Melan A protein antibody Melanoma antigen recognized by T cells 1 antibody Melanoma antigen recognized by T-cells 1 antibody MLAN A antibody MLANA antibody OTTHUMP00000021036 antibody OTTHUMP00000021037 antibody OTTHUMP00000021038 antibody Protein Melan-A antibody
Accession No.	Swiss-Prot#:Q16655
Uniprot	Q16655
GeneID	2315;
Excitation Emission	AF350: 346nm/442nm
	AF405: 401nm/421nm
	AF488: 493nm/519nm
	AF555: 555nm/565nm
	AF594: 591nm/614nm
	AF647: 651nm/667nm
	AF680: 679nm/702nm
	AF750: 749nm/775nm
Calculated MW	20
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°C in dark for 6 months

Application Details

Suggested Dilution:

AF350 conjugated: most applications: 1: 50 - 1: 250

AF405 conjugated: most applications: 1: 50 - 1: 250

AF488 conjugated: most applications: 1: 50 - 1: 250

AF555 conjugated: most applications: 1: 50 - 1: 250

AF594 conjugated: most applications: 1: 50 - 1: 250

AF647 conjugated: most applications: 1: 50 - 1: 250

AF680 conjugated: most applications: 1: 50 - 1: 250

AF750 conjugated: most applications: 1: 50 - 1: 250

Biotin conjugated: working with enzyme-conjugated streptavidin, most applications: 1: 50 - 1: 1,000

Background

Melanoma-associated antigens recognized by cytotoxic T lymphocytes (CTL) have been grouped into three categories: melanocyte differentiation antigens, cancer/testis-specific antigens and mutated or aberrantly expressed antigens. Many of these antigens consist of peptides that are presented to T cells by HLA molecules; they represent potential targets for cancer immunotherapy. Melan-A (also designated MART-1) is a melanocyte differentiation antigen that is specific to melanomas, melanocyte cell lines and retina. Melan-A peptide is recognized by most HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes in patients with melanoma. Antimelanoma cytotoxic T lymphocytes can be generated with a Melan-A peptide, implicating Melan-A as a potential candidate for antigen-specific immunotherapy in melanoma patients.

Note: This product is for in vitro research use only